Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for 3SBIO?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥2.80B in FY2016 to CN¥17.70B in FY2025 (9-year CAGR +22.7%).
- Profitable in every fiscal year across 2016–2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 6.38 | 6.87 | 7.82 | 9.11 | 17.7 |
| YoY | 14.2% | 7.6% | 13.8% | 16.5% | 94.3% |
| Net Income (CNY B) | 1.65 | 1.92 | 1.55 | 2.09 | 8.48 |
| YoY | 97.6% | 16.0% | -19.1% | 34.9% | 305.8% |
| Operating Cash Flow (CNY B) | 1.58 | 2.13 | 2.08 | 3.20 | 9.67 |
| ROE | 14.4% | 15.2% | 11.5% | 14.2% | 39.8% |
| Gross Margin | 82.7% | 82.6% | 85.0% | 86.0% | 92.4% |
| Net Margin | 25.9% | 27.9% | 19.8% | 23.0% | 47.9% |
| Debt-to-Assets | 23.7% | 30.2% | 30.1% | 25.5% | 16.0% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 2.80 | 3.73 | 4.58 | 5.32 | 5.59 | 6.38 | 6.87 | 7.82 | 9.11 | 17.7 |
| YoY | — | 33.5% | 22.7% | 16.0% | 5.1% | 14.2% | 7.6% | 13.8% | 16.5% | 94.3% |
| Net Income (CNY B) | 0.71 | 0.94 | 1.28 | 0.97 | 0.84 | 1.65 | 1.92 | 1.55 | 2.09 | 8.48 |
| YoY | — | 31.3% | 36.5% | -23.8% | -14.2% | 97.6% | 16.0% | -19.1% | 34.9% | 305.8% |
| Operating Cash Flow (CNY B) | 1.00 | 1.07 | 1.15 | 1.89 | 1.34 | 1.58 | 2.13 | 2.08 | 3.20 | 9.67 |
| ROE | 10.9% | 13.4% | 16.0% | 10.7% | 8.2% | 14.4% | 15.2% | 11.5% | 14.2% | 39.8% |
| Gross Margin | 85.6% | 81.9% | 80.9% | 82.6% | 81.0% | 82.7% | 82.6% | 85.0% | 86.0% | 92.4% |
| Net Margin | 25.5% | 25.0% | 27.9% | 18.3% | 15.0% | 25.9% | 27.9% | 19.8% | 23.0% | 47.9% |
| Debt-to-Assets | 38.7% | 44.5% | 35.6% | 30.0% | 25.9% | 23.7% | 30.2% | 30.1% | 25.5% | 16.0% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
- Watch
-
Watch
Auditor ChangeMaterial Events
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$0.252 per share, or 1.71% yield at closing price; last full fiscal year: HK$0.252 (payout ratio 6.8%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.